At the end of 2017, a group of industrial veterans and scientists with decades of experience in drug research and development established Accro Bioscience (Suzhou) Limited. Wholly owned by Accro Bioscience (HK) Limited, Accro Bioscience (Suzhou) Limited is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases.
Through harnessing the power of science and drug discovery, the Company has developed a robust portfolio with innovative compounds in various stages spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 was approved for clinical testing by FDA and NMPA in December 2021 and August 2022, respectively. AC-003 has completed the Phase 1 clinical trial between China and the United States in August 2023 and achieved positive results, and is ready to dose patients for GVHD. The company’s RIKP2 inhibitor AC-101 was approved by HREC in March 2023 for clinical testing and is about to complete its Phase I clinical trial in Australia. In addition, AC-201, a selective TYK2/JAK1 inhibitor with huge potential for treating inflammatory and autoimmune diseases, was approved by HREC and NMPA in May 2023 and September 2023, a Phase I clinical trial is underway in Australia and China. The company has multiple compounds in the PCC and preclinical research and development stages. The company owns global rights of all its assets with more than 10 patents issued in China, Japan, Korea, US and EU, etc.
The Company is headquartered in the BioBAY of Suzhou Industrial Park.